Tango Therapeutics, Inc. · NASDAQ:TNGX
Tango Therapeutics — PDAC Investor Presentation (October 2026)
35 slides from Tango Therapeutics's conference presentation, Oct 23, 2026
Slide 1: PDAC Investor Presentation
PDAC Investor Presentation October 23, 2026
Slide 2: Disclaimer and safe harbor statement
Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or
Slide 3: Agenda for today
Agenda for today Introduction Malte Peters, MD | President and Chief Executive Officer Vopimetostat + daraxonrasib combination data update Brian Wolpin, MD | Dana-Farber Cancer Institute & Harvard Medical School Vopimetostat registration and expansion strategy in PDAC Adam Crystal, MD, PhD | Preside
Slide 4: Introduction
Introduction Malte Peters, MD, President and Chief Executive Officer 4
Slide 5: Leadership in PRMT5 inhibition anchors broad value creation opportunity
Leadership in PRMT5 inhibition anchors broad value creation opportunity CLINICALLY PHASE 3-READY DIFFERENTIATED EXPANSION VALIDATED DESIGN Potentially Defined regulatory Demonstrated Leading the field differentiated path combinability efficacy profile 82% ORR Efficient Phase 3 design Clinical data a
Slide 6: ~60,000 U.S. pancreatic cancer patients per year
~60,000 U.S. pancreatic cancer patients per year ~60,000 ~24,0001 ~36,000 MTAP-WT PDAC patients MTAP-deleted diagnosed/year ~20,000 ~30,000 1L treatment2 MTAP-deleted MTAP-WT Chemo-free regimens may ~9,200 ~13,800 increase patient access and MTAP-deleted MTAP-WT 2L treatment2 benefit Patient populat
Slide 7: Brian Wolpin is a leader in the study and treatment of pancreatic cancer
Brian Wolpin is a leader in the study and treatment of pancreatic cancer Professor of Medicine, Harvard Medical School Robert T. & Judith B. Hale Chair in Pancreatic Cancer, Dana-Farber Cancer Institute Director, Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer Cen
Slide 8: Vopimetostat + daraxonrasib combination data update
Vopimetostat + daraxonrasib combination data update Brian Wolpin, MD, MPH Dana-Farber Cancer Institute & Harvard Medical School 8
Slide 9: Evolution of standard of care for pancreatic cancer
Evolution of standard of care for pancreatic cancer CHEMOTHERAPY RAS INHIBITORS RAS INHIBITORS + PRMT5 INHIBITORS Increased response rate and Current standard; RASONQUE FDA approved based prolonged durability; lower rates Limited efficacy on improved PFS and OS of rash observed1 Current Approved + L
Slide 10: Vopimetostat selectively inhibits the cell essential gene PRMT5 in MTAP deleted cancer cells
Vopimetostat selectively inhibits the cell essential gene PRMT5 in MTAP deleted cancer cells X deletion causes MTA accumulation only in cancer cells X MTAP MTA MTA activates PRMT5 partially inhibits PRMT5 SAM MTA MTA by replacing SAM in normal cells Vopimetostat PRMT5 inhibits PRMT5 only in MTAP-del
Slide 11: PRMT5 inhibition plus RAS inhibition is synergistic preclinically
PRMT5 inhibition plus RAS inhibition is synergistic preclinically Vopimetostat + Daraxonrasib: CAPAN1 Vopimetostat + Zoldonrasib: KP4 MTAP-null, KRASG12V PDAC CDX MTAP-null, KRASG12D PDAC CDX 20 mpk BID 5 mpk QD 20 mpk BID vopimetostat + 20 mpk BID 100 mpk QD 100 mpk QD zoldonrasib + Vehicle Vehicle
Slide 12: First PRMT5 inhibitor combined with RAS inhibitors in the clinic
First PRMT5 inhibitor combined with RAS inhibitors in the clinic Phase 1 dose escalation trial Vopimetostat + daraxonrasib: • Dose escalation range: Any RAS mut vopimetostat + 200 mg – 250 mg vopimetostat QD 2L+ MTAP-del/ daraxonrasib + 100 mg daraxonrasib QD RAS mut pancreatic and lung cancer vopim
Slide 13: Patient baseline characteristics
Patient baseline characteristics Vopimetostat + daraxonrasib Vopimetostat + daraxonrasib Vopimetostat + zoldonrasib (PDAC) N=29 (NSCLC) N=5 (PDAC) N=39a Sex, male, n (%) 12 (41.4) 3 (60) 21 (53.8) Age, years, median (range) 66 (44, 74) 55 (38, 71) 66 (37, 81) 0 2 (6.9)b - - Prior anti-cancer 1 10 (3
Slide 14: Vopimetostat + daraxonrasib in MTAP-del 2/3L PDAC: ORR 82%
Vopimetostat + daraxonrasib in MTAP-del 2/3L PDAC: ORR 82% 20 N=22 Best Change in Tumor Size from Baseline (%) ORR 82% 0 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL1 DL2 DL1 DL1 DL1 DL2 DCR 100% -20 All responses now confirmed -40 -60 Legend: Note: ■ Partial Response (PR) 13/2
Slide 15: Consistent and promising results across PDAC and NSCLC
Consistent and promising results across PDAC and NSCLC Median duration of follow-up 20 PDAC: 7.1 months (3.3-12.5) NSCLC: 7.7 months (3.8-12.3) Line of Therapy Best Change in Tumor Size from Baseline (%) 1 3 3 2 2 2 3 3 3 3 3 2 2 3 2 4 3 3 3 3 3 3 3 2 1 3 2 0 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1
Slide 16: Vopimetostat + daraxonrasib in MTAP-del PDAC: 88% 9-month PFS rate
Vopimetostat + daraxonrasib in MTAP-del PDAC: 88% 9-month PFS rate 3 3 Key Metrics 3 2 3 • 88% 9-month PFS rate in 2 PDAC (95% CI: 60, 97) 2 3 • 59% of PDAC patients are Line of Therapy 1 3 3L 2 2 3 3 3 3 2 Legend: 3 2 ■ Partial Response (PR) 3 ■ Stable Disease (SD) 3 Ongoing Therapy 1 0 1 2 3 4 5 6
Slide 17: Strong PFS trends in both second and third line MTAPdel PDAC
Strong PFS trends in both second and third line MTAPdel PDAC Key Metrics • 88% 9-month PFS rate (95% CI: 60, 97) • No disease progression in 2L patients No. at Risk LoT 0 2 4 6 8 10 12 2 7 7 5 5 3 0 3 13 13 9 5 5 3 0 Alla 22 21 15 11 9 3 0 Data extract 20 August 2026. PDAC, pancreatic ductal adenoca
Slide 18: Vopimetostat + daraxonrasib was generally well-tolerated at dose level 1
Vopimetostat + daraxonrasib was generally well-tolerated at dose level 1 DL1: PDAC DL1:NSCLC DL2: PDAC n, (%) (n=25) (n=5) (n=4) Safety Summary Any TRAE 19 (76.0) 5 (100.0) 4 (100.0) • No new safety signals Grade 1-2 9 (36.0) 4 (80.0) 1 (25.0) observed Grade 3 10 (40.0) 1 (20.0) 3 (75.0) • No discon
Slide 19: Vopimetostat + daraxonrasib was generally well-tolerated at dose level 1
Vopimetostat + daraxonrasib was generally well-tolerated at dose level 1 DL1: PDAC DL1:NSCLC DL2: PDAC n, (%) (n=25) (n=5) (n=4) Safety Summary TRAEs occurring in All Grade All Grade All Grade ≥15% of Patients Grades 3 Grades 3 Grades 3 • No new safety signals observed Rasha 11 (44.0) - 5 (100.0) -
Slide 20: Vopimetostat + daraxonrasib demonstrated favorable RAS associated safety profile
Vopimetostat + daraxonrasib demonstrated favorable RAS associated safety profile Vopimetostat 200 mg + daraxonrasib 100 mg (PDAC) Pharmacokinetics and safety n=25 (TRAEs, % patients, Grade 1-3) Dose level 1 Stomatitis/mucositis 48% • Daraxonrasib AUC: 4303 hr*ng/ml (n=20, CV 40%) Rash 44% − Similar
Slide 21: Clinically meaningful exposures and limited variability supportive of Phase 3 development
Clinically meaningful exposures and limited variability supportive of Phase 3 development Vopimetostat (ng/ml) Daraxonrasib (ng/ml) Time (Hour) CV AUC0-24h (ng*h/mL) | Mean ± SD Vopimetostat DL1 (n=18) 38% 3815 ± 1444 Data extract 20 August 2026. Daraxonrasib DL1 (n=20) 40% 4303 ± 1721 21
Slide 22: Vopimetostat registration path
Vopimetostat registration path Adam Crystal, MD, PhD, President of Research and Development 22
Slide 23: Vopimetostat + daraxonrasib: anticipated path to PDAC registration
Vopimetostat + daraxonrasib: anticipated path to PDAC registration LEAD PROGRAM Vopimetostat + daraxonrasib ~20,0001 Defined 1L MTAP-del patients annually U.S. registration path Larger near-term PDAC opportunity Design informed by FDA guidance 82% 88% Favorable safety + ORR* 9-mo PFS rate full targe
Slide 24: Phase 3 study in 1L, MTAP-del PDAC anticipated to start 1H 2027
Phase 3 study in 1L, MTAP-del PDAC anticipated to start 1H 2027 Primary Endpoints Vopimetostat + daraxonrasib 1L MTAP-del • Dual primary endpoints: metastatic 1:1 ORR and PFS pancreatic cancer randomization N = 484 SOC chemo • OS as key secondary endpoint • Dose level 1 selected Key inclusion criter
Slide 25: Advancing development path in 1L and 2L PDAC
Advancing development path in 1L and 2L PDAC Vopimetostat + daraxonrasib PDAC front line strategy supported by regulatory discussions Study Objectives & Path Details Primary Readout Potential Regulatory Outcomes Randomized 1L PATH ORR Controlled Trial vs. • Potential 1L approval PFS SOC chemo • Asse
Slide 26: Leadership in PRMT5 inhibition
Leadership in PRMT5 inhibition Adam Crystal, MD, PhD 26
Slide 27: Leadership in PRMT5 supports opportunities for indication expansion
Leadership in PRMT5 supports opportunities for indication expansion Biologic PDAC Additional Foundation Vopimetostat + RAS inhibitors Opportunities • PRMT5i + RAS/MAPK • Clinical activity shows that • Clinical synergy with MAPK inhibition is synergistica the combination biology pathway may extend •
Slide 28: Vopimetostat inhibited PRMT5 in MTAP WT cells, clinically
Vopimetostat inhibited PRMT5 in MTAP WT cells, clinically Pharmacokinetics Pharmacodynamics Safety Vopimetostat inhibited MTAP WT tissue At 200 mg vopimetostat PRMT5 in MTAP wild type MTAP del tumor results in on target cells related adverse events: • Fatigue • Clinical exposure in DL1 = IC50 in MTA
Slide 29: Vopimetostat potentiates daraxonrasib in MTAP-WT PDAC cell lines at the exposure achieved clinically
Vopimetostat potentiates daraxonrasib in MTAP-WT PDAC cell lines at the exposure achieved clinically Vopimetostat + daraxonrasib in vitro activity Key observations • Improved clinical activity in MTAP-WT PDAC cell Maximum Efficacy Maximum Efficacy lines with vopimetostat + (% of DMSO) (% of DMSO) da
Slide 30: Efficient path to expand the PRMT5 opportunity
Efficient path to expand the PRMT5 opportunity Potential for combination benefit to extend beyond MTAP-deleted cancers Clinically Enroll MTAP-WT Potential to reach validated PDAC cohort more patients in combination Anticipated ~25-patient PDAC & beyond vopimetostat + POC cohort MTAP-WT proof of conc
Slide 31: Upcoming milestones and financial highlights
Upcoming milestones and financial highlights Matthew Gall, Chief Financial Officer 31
Slide 32: Near-term anticipated milestones support advancement of vopimetostat clinical development
Near-term anticipated milestones support advancement of vopimetostat clinical development and efficient expansion opportunities Advance NSCLC Expand RAS Opportunity Advance Lead PDAC Program development strategy 2H26 1H27 January 2027 Initiate Phase 1/2 Initiate Phase 3 vopimetostat + Release TNG456
Slide 33: Conclusion
Conclusion Malte Peters, MD, President and Chief Executive Officer 33
Slide 34: Compelling PDAC data support our registration strategy and broader franchise potential
Compelling PDAC data support our registration strategy and broader franchise potential VALIDATED REGISTRATION- LAUNCH BROADER CLINICAL PROFILE DIRECTED PREPARATION VOPIMETOSTAT DEVELOPMENT FRANCHISE POTENTIAL Compelling activity, Focus shifts from Organizational Combinability and MTAP-WT durability
Slide 35: Tango Therapeutics
Ai; TANGO therapeutics
Tango Therapeutics — PDAC Investor Presentation (October 2026) on 6ix